Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis

Christopher T. Lohans, Jürgen Brem, Christopher J. Schofield
Christopher T. Lohans
Chemistry Research Laboratory, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher T. Lohans
Jürgen Brem
Chemistry Research Laboratory, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jürgen Brem
Christopher J. Schofield
Chemistry Research Laboratory, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher J. Schofield
DOI: 10.1128/AAC.01224-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

Metallo-β-lactamases (MBLs) threaten the clinical utility of β-lactam antibiotics by hydrolyzing penicillins, cephalosporins, and carbapenems. Moreover, they can also hydrolyze all clinically used inhibitors (e.g., clavulanic acid, sulbactam, and tazobactam) that protect β-lactam antibiotics from the activity of multidrug-resistant bacteria (1). Even the diazabicyclooctane (DBO)-based serine-β-lactamase (SBL) inhibitor avibactam, which was recently approved by the FDA, is hydrolyzed slowly by some MBLs (2).

The combination of avibactam and the monobactam antibiotic aztreonam has recently passed phase II clinical trials for the treatment of infections by multidrug-resistant Gram-negative bacteria producing MBLs (3). While SBL-mediated resistance to aztreonam has long been known via the evolution of SBLs (4), MBLs are not thought to hydrolyze aztreonam (5–7). Due to structural similarities between avibactam and aztreonam (Fig. 1A), particularly with respect to the sulfonate/sulfate substituent on the β-lactam/urea nitrogen, we were interested in examining the interaction between more recently discovered MBLs and aztreonam and the potential for new clinically relevant MBLs with monobactam hydrolyzing activity.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Hydrolysis of avibactam and aztreonam by NDM-1. (A) Structures of avibactam and aztreonam. (B) Extent of aztreonam (100 μM) hydrolysis by VIM-4, BcII, and NDM-1 (all 10 μM) after 16 h. Hydrolysis was monitored by NMR spectroscopy (700 MHz); the peaks labeled with an asterisk correspond to the aztreonam proton indicated with an asterisk in panel A, while the peaks labeled with two asterisks indicate the hydrolyzed product. (C) Extent of hydrolysis of a mixture of aztreonam (ATM; 1 mM) and avibactam (AVI; 1 mM) by NDM-1 (10 μM) after 50 min with 100 μM ZnCl2–50 mM Tris-d11 (pH 7.5)–10% D2O. The addition of d-captopril (500 μM) or EDTA (2 mM) or removal of ZnCl2 inhibited aztreonam hydrolysis. (D) Preliminary kinetic characterization of avibactam and aztreonam hydrolysis by NDM-1 as monitored by NMR and UV-Vis analysis. The NMR studies used 10 μM NDM-1, 100 μM ZnCl2, and the indicated concentration of avibactam or aztreonam in 50 mM Tris-d11 (pH 7.5)–10% D2O. The UV-Vis studies (monitored at 230 nm) used 10 μM NDM-1, 20 μM ZnCl2, and the indicated concentration of avibactam in 5 mM HEPES, pH 7.5 (2). Nonlinear regression analyses were performed using Prism 7 (GraphPad). (E and F) Hydrolysis of (E) aztreonam and (F) avibactam by a panel of β-lactamases covering classes A (black), B (red), C (blue), and D (green). Hydrolysis was measured by NMR after 24 h for samples consisting of enzyme (10 μM) and avibactam (400 μM) or aztreonam (1 mM) in 50 mM Tris-d11 (pH 7.5)–10% D2O.

We tested the hydrolysis of aztreonam by recombinant enzymes covering all three subclasses of MBLs (i.e., B1, B2, and B3). Following overnight incubation of a 1:10 ratio of MBL and aztreonam, the extent of hydrolysis was determined by nuclear magnetic resonance (NMR) spectroscopy. While Verona integron-encoded MBL-1 (VIM-1) (subclass B1), VIM-4 (B1), CphA (B2), and L1 (B3) did not hydrolyze aztreonam (within our limits of detection), the model MBL BcII (B1) showed partial hydrolysis, and New Delhi MBL-1 (NDM-1) (B1) fully hydrolyzed aztreonam under our assay conditions (Fig. 1B). The BcII data are in broad agreement with the previously observed “nonproductive” binding of aztreonam to BcII (8). Interestingly, no interaction between aztreonam and NDM-1 was observed by 19F-NMR analysis (9), suggesting that the binding interaction (e.g., Km) is quite weak. Therefore, more detailed kinetic analyses were performed.

The hydrolysis of aztreonam by NDM-1 was monitored over a shorter time scale (Fig. 1C), yielding a specific activity of 3.7 ± 0.4 nmol min−1 mg−1 using 10 μM NDM-1 and 1 mM aztreonam. The dependence of aztreonam hydrolysis on NDM-1 activity was confirmed by inhibition in the presence of EDTA and d-captopril, both inhibitors of MBLs (Fig. 1C). The hydrolysis of avibactam by NDM-1 was also shown by NMR analysis, which indicated that avibactam is hydrolyzed more quickly than aztreonam (Fig. 1C).

The kinetics of avibactam and aztreonam hydrolysis by NDM-1 were further investigated by UV-visible (UV-Vis) spectroscopy and NMR spectroscopy (Fig. 1D). Due to poor substrate turnover and the limitations associated with these detection methods, a full kinetic characterization was not possible; while the values obtained are expected to be imprecise, they may serve as estimates of substrate affinity and turnover. Although apparent Km and kcat values of ∼3 mM and ∼0.02 s−1 were obtained for the hydrolysis of avibactam by NDM-1 as monitored by UV-Vis, the limited substrate concentrations prevented accurate nonlinear regression analysis (Fig. 1D). Instead, based on the NMR studies which employed a wider range of substrate concentrations, avibactam had an apparent Km of ∼24 mM and an apparent kcat of ∼0.15 s−1 with NDM-1.

Aztreonam had an apparent Km of ∼9 mM and an apparent kcat of ∼0.014 s−1 with NDM-1 under the NMR assay conditions. By comparison, BcII had an approximate maximal kcat of ∼3 × 10−4 s−1 with aztreonam, while the other MBLs tested (for which we did not observe aztreonam hydrolysis by NMR) had calculated maximal kcat values of ∼6 × 10−5 s−1 based on the sensitivity limits of the NMR assay. To provide context with other β-lactamases, the kcat values for avibactam and aztreonam with NDM-1 are comparable to those determined previously for class D β-lactamases with carbapenems (10) and for class C β-lactamases with cephalosporins (11); these classes of enzymes are thought to contribute to resistance to these antibiotics in vivo.

The hydrolysis of avibactam and aztreonam was tested with a panel of 12 β-lactamases, as monitored by NMR (Fig. 1E and F). The β-lactamases tested belong to classes A (TEM-1, CTX-M-15), B (BcII, NDM-1, VIM-1, VIM-4, CphA, L1), C (AmpC), and D (OXA-10, OXA-23, OXA-48). While aztreonam was hydrolyzed efficiently by the class A and class D β-lactamases tested, the class C β-lactamase AmpC (from Pseudomonas aeruginosa) poorly catalyzed aztreonam hydrolysis. As indicated above, while most MBLs tested did not hydrolyze aztreonam, NDM-1 (and BcII to a lesser extent) displayed activity. Although no avibactam hydrolysis was observed for the class A, C, and D β-lactamases tested, MBLs belonging to subclasses B1, B2, and B3 all catalyzed avibactam hydrolysis (Fig. 1F).

These results challenge the widely held view that MBLs cannot hydrolyze aztreonam. Although the hydrolysis of avibactam and aztreonam by NDM-1 at the rate that we observed may well not be clinically relevant, the evolution of MBLs to more efficiently hydrolyze both substrates is likely. This proposal is analogous to what has been observed with the TEM SBLs; while TEM-1 does not efficiently hydrolyze aztreonam, TEM mutants with increased aztreonam hydrolyzing activity have been identified (12). Furthermore, MBL variants with greater activity may already exist in clinical isolates. Therefore, the potential for MBL-mediated resistance should be considered in evaluating the clinical use of avibactam and aztreonam, individually or in combination, as well as of other DBOs and monobactams.

ACKNOWLEDGMENTS

We thank the Medical Research Council and the Wellcome Trust for funding our work on MBLs. C.T.L. is grateful to the Canadian Institutes of Health Research.

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Prosperi-Meys C,
    2. Llabres G,
    3. de Seny D,
    4. Soto RP,
    5. Valladares MH,
    6. Laraki N,
    7. Frere JM,
    8. Galleni M
    . 1999. Interaction between class B β-lactamases and suicide substrates of active-site serine β-lactamases. FEBS Lett443:109–111. doi:10.1016/S0014-5793(98)01689-5.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Abboud MI,
    2. Damblon C,
    3. Brem J,
    4. Smargiasso N,
    5. Mercuri P,
    6. Gilbert B,
    7. Rydzik AM,
    8. Claridge TD,
    9. Schofield CJ,
    10. Frère JM
    . 2016. Interaction of avibactam with class B metallo-β-lactamases. Antimicrob Agents Chemother60:5655–5662. doi:10.1128/AAC.00897-16.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Fernandes P,
    2. Martens E
    . 2017. Antibiotics in late clinical development. Biochem Pharmacol133:152–163. doi:10.1016/j.bcp.2016.09.025.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Quinn JP,
    2. Miyashiro D,
    3. Sahm D,
    4. Flamm R,
    5. Bush K
    . 1989. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother33:1451–1456. doi:10.1128/AAC.33.9.1451.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Walsh TR
    . 2005. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria. Clin Microbiol Infect11(Suppl 6):2–9. doi:10.1111/j.1469-0691.2005.01264.x.
    OpenUrlCrossRef
  6. 6.↵
    1. Crandon JL,
    2. Nicolau DP
    . 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother57:3299–3306. doi:10.1128/AAC.01989-12.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Marshall S,
    2. Hujer AM,
    3. Rojas LJ,
    4. Papp-Wallace KM,
    5. Humphries RM,
    6. Spellberg B,
    7. Hujer KM,
    8. Marshall EK,
    9. Rudin SD,
    10. Perez F,
    11. Wilson BM,
    12. Wasserman RB,
    13. Chikowski L,
    14. Paterson DL,
    15. Vila AJ,
    16. van Duin D,
    17. Kreiswirth BN,
    18. Chambers HF,
    19. Fowler VG Jr,
    20. Jacobs MR,
    21. Pulse ME,
    22. Weiss WJ,
    23. Bonomo RA
    . 2017. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae. Antimicrob Agents Chemother61:e02243-16. doi:10.1128/AAC.02243-16.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Poeylaut-Palena AA,
    2. Tomatis PE,
    3. Karsisiotis AI,
    4. Damblon C,
    5. Mata EG,
    6. Vila AJ
    . 2007. A minimalistic approach to identify substrate binding features in B1 metallo-β-lactamases. Bioorg Med Chem Lett17:5171–5174. doi:10.1016/j.bmcl.2007.06.089.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Rydzik AM,
    2. Brem J,
    3. van Berkel SS,
    4. Pfeffer I,
    5. Makena A,
    6. Claridge TD,
    7. Schofield CJ
    . 2014. Monitoring conformational changes in the NDM-1 metallo-β-lactamase by 19F NMR spectroscopy. Angew Chem Int Ed Engl53:3129–3133. doi:10.1002/anie.201310866.
    OpenUrlCrossRefWeb of Science
  10. 10.↵
    1. Potron A,
    2. Rondinaud E,
    3. Poirel L,
    4. Belmonte O,
    5. Boyer S,
    6. Camiade S,
    7. Nordmann P
    . 2013. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae. Int J Antimicrob Agents41:325–329. doi:10.1016/j.ijantimicag.2012.11.007.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Rodríguez-Martínez JM,
    2. Poirel L,
    3. Nordmann P
    . 2009. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother53:1766–1771. doi:10.1128/AAC.01410-08.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Cantu C III,
    2. Huang W,
    3. Palzkill T
    . 1996. Selection and characterization of amino acid substitutions at residues 237–240 of TEM-1 β-lactamase with altered substrate specificity for aztreonam and ceftazidime. J Biol Chem271:22538–22545. doi:10.1074/jbc.271.37.22538.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis
Christopher T. Lohans, Jürgen Brem, Christopher J. Schofield
Antimicrobial Agents and Chemotherapy Nov 2017, 61 (12) e01224-17; DOI: 10.1128/AAC.01224-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis
Christopher T. Lohans, Jürgen Brem, Christopher J. Schofield
Antimicrobial Agents and Chemotherapy Nov 2017, 61 (12) e01224-17; DOI: 10.1128/AAC.01224-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Azabicyclo Compounds
aztreonam
beta-lactamases
antibiotic resistance
avibactam
aztreonam
beta-lactamases
metalloenzymes
monobactams

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596